natgillin/translations-raw huggingface dataset:
Mean pulmonary systolic blood pressure decreased by 9%.
Srednji pulmonalni sistolički krvni tlak snizio se za 9%.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Sildenafil Actavis and when you did.
U slučaju hitne medicinske intervencije, morate upozoriti svog liječnika, ljekarnika ili medicinsku sestru da ste uzeli Sildenafil Actavis te kada ste ga uzeli.
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti i reproduktivne i razvojne toksičnosti.
Because not all adverse reactions are reported the frequencies of these reactions cannot be reliably determined.
S obzirom da sve nuspojave nisu prijavljene, učestalost tih nuspojava nije moguće pouzdano odrediti.
Use in adults
Primjena u odraslih osoba
In vitro studies
In vitro ispitivanja
In vivo studies
In vivo ispitivanja
Do not take Sildenafil Actavis with other medicines unless your doctor tells you that you can.
Nemojte uzimati Sildenafil Actavis s drugim lijekovima, osim ako Vam tako nije rekao liječnik.
- If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy
- Ako ste ikada imali gubitak vida zbog nearteritične prednje ishemijske optičke neuropatije
What Sildenafil Actavis is and what it is used for What you need to know before you take Sildenafil Actavis How to take Sildenafil Actavis Possible side effects
Što je Sildenafil Actavis i za što se koristi Što morate znati prije nego počnete uzimati Sildenafil Actavis Kako uzimati Sildenafil Actavis Moguće nuspojave
This is most likely to happen within 4 hours after taking Sildenafil Actavis.
To će se najvjerojatnije dogoditi unutar 4 sata nakon uzimanja lijeka Sildenafil Actavis.
If you have an erection which lasts for more than 4 hours, you should contact a doctor immediately.
Ako imate erekciju koja traje dulje od 4 sata, odmah se obratite svom liječniku.
Sildenafil Actavis will only help you to get an erection if you are sexually stimulated.
Sildenafil Actavis će Vam pomoći u postizanju erekcije jedino ako ste seksualno stimulirani.
Of note, most, but not all, of the men who experienced these side effects had heart problems before taking this medicine.
Potrebno je napomenuti kako je većina muškaraca, ali ne svi, koja je imala navedene nuspojave, imala poteškoće sa srcem već prije uzimanja ovog lijeka.
You should take Sildenafil Actavis about one hour before sexual activity.
Trebate uzeti Sildenafil Actavis oko jedan sat prije planirane spolne aktivnosti.
If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Sildenafil Actavis.
Ako uzimate lijekove poznate kao inhibitori proteaze, na primjer za liječenje infekcije HIV-om, liječnik Vam može propisati najnižu početnu dozu (25 mg) lijeka Sildenafil Actavis.
Sildenafil Actavis tablets may interfere with some medicines, especially those used to treat chest pain.
Sildenafil Actavis tablete mogu međusobno djelovati s nekim lijekovima, osobito onima koji se koriste za liječenje boli u prsima.
Certain patients have experienced these symptoms when taking sildenafil with alpha-blockers.
Određeni bolesnici imali su te simptome prilikom uzimanja sildenafila s alfa-blokatorima.
To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking Sildenafil Actavis.
Kako biste izvukli najviše koristi od lijeka, savjetuje se da ne uzimate veće količine alkohola prije uzimanja lijeka Sildenafil Actavis.
Sildenafil Actavis should not be given to individuals under the age of 18.
Sildenafil Actavis se ne smije davati osobama mlađim od 18 godina.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000)).
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000)).
Special considerations for patients with kidney or liver problems You should tell your doctor if you have kidney or liver problems.
Posebna upozorenja za bolesnike s poremećajem bubrega ili jetre Obavijestite svog liječnika ako imate poteškoće s bubrezima ili jetrom.
1 film-coated tablet 2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated tablets 24 film-coated tablets
1 filmom obložena tableta 2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 12 filmom obloženih tableta 24 filmom obložene tablete
Patients should be advised that in the event of any sudden visual defect, they should stop taking Sildenafil Actavis and consult a physician immediately (see section 4.3).
Bolesnike treba savjetovati da u slučaju bilo kakvog iznenadnog poremećaja vida prestanu uzimati Sildenafil Actavis i odmah zatraže savjet liječnika (vidjeti dio 4.3).
What Sildenafil Actavis is and what it is used for
Što je Sildenafil Actavis i za što se koristi
You should not take Sildenafil Actavis if you are a woman.
Ne smijete uzimati Sildenafil Actavis ako ste žena.
As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to Sildenafil Actavis, before driving or operating machinery.
Budući da su omaglica i poremećaj vida zabilježeni u kliničkim ispitivanjima sa sildenafilom, bolesnici moraju biti svjesni na koji način oni reagiraju na Sildenafil Actavis prije upravljanja vozilima ili rada sa strojevima.
After a single oral dose of 100 mg, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (CV 40%).
Nakon jednokratne oralne doze od 100 mg srednja maksimalna ukupna koncentracija sildenafila u plazmi iznosi približno 440 ng/ml (CV 40%).
The mean steady state volume of distribution (Vd) for sildenafil is 105 l, indicating distribution into the tissues.
Srednji volumen distribucije u stanju dinamičke ravnoteže (Vd) za sildenafil iznosi 105 l što upućuje na distribuciju u tkiva.
Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through post-marketing surveillance
Tablica 1: Medicinski značajne nuspojave zabilježene s incidencijom većom od placeba u kontroliranim kliničkim ispitivanjima i medicinski značajne nuspojave zabilježene u razdoblju nakon stavljanja lijeka u promet
Sildenafil Actavis potentiates the hypotensive effect of nitrates (see section 4.3).
Sildenafil Actavis pojačava hipotenzivne učinke nitrata (vidjeti dio 4.3).
You should not take Sildenafil Actavis more than once a day.
Sildenafil Actavis se ne smije uzeti više od jedanput na dan.
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50>150 µM).
Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50 >150 mM).
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing.
U zdravih dobrovoljaca koji su primali sildenafil (100 mg u jednokratnoj dozi) manje od 0,0002% (prosječno 188 ng) primijenjene doze prisutno je u ejakulatu 90 minuta nakon doziranja.
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that Sildenafil Actavis will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 mM, nije vjerojatno da će Sildenafil Actavis promijeniti klirens supstrata tih izoenzima.
Sildenafil Actavis can cause dizziness and can affect vision.
Sildenafil Actavis može uzrokovati omaglicu i utjecati na vid.
Sildenafil Actavis is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
Sildenafil Actavis je indiciran u odraslih muškaraca s erektilnom disfunkcijom, odnosno nemogućnošću postizanja ili održavanja penilne erekcije dostatne za zadovoljavajuću seksualnu aktivnost.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 79% and 200% respectively.
Nadalje, vrijednosti AUC i Cmax N-dezmetil metabolita bile su značajno povećane, 79% odnosno 200%.
Sildenafil Actavis is a treatment for adult men with erectile dysfunction, sometimes known as impotence.
Sildenafil Actavis je lijek namijenjen liječenju odraslih muškaraca s erektilnom disfunkcijom, ponekad zvanom impotencija.
PDE5 inhibitors, such as Sildenafil Actavis have been shown to increase the hypotensive effects of this medicine.
PDE5 inhibitori, kao što je Sildenafil Actavis su pokazali da povećavaju hipotenzivne učinke ovog lijeka.
Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly.
Pojedini bolesnici koji uzimaju alfa-blokatore za liječenje visokog krvnog tlaka ili povećanja prostate mogu imati omaglicu ili ošamućenost što može biti uzrokovano sniženjem krvnog tlaka nakon naglog uspravljanja u sjedeći ili stojeći položaj.
Your doctor may start you on a lower dose (25 mg) of Sildenafil Actavis.
Liječnik Vas može staviti na početnu nižu dozu (25 mg) lijeka Sildenafil Actavis.
6.4 Special precautions for storage Store below 30°C.
POSEBNE MJERE ČUVANJA Čuvati na temperaturi ispod 30°C.
In order for Sildenafil Actavis to be effective, sexual stimulation is required.
Kako bi Sildenafil Actavis djelovao, neophodna je seksualna stimulacija.
Pregnancy, breast-feeding and fertility Sildenafil Actavis is not indicated for use by women.
Trudnoća, dojenje i plodnost Sildenafil Actavis nije namijenjen za primjenu u žena.
There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration.
Nema informacija o sigurnosti primjene sildenafila u bolesnika s poremećajima krvarenja ili aktivnim peptičkim ulkusom.
In addition, the frequency of medically important adverse reactions reported from post-marketing experience is included as not known.
Pored toga, učestalost medicinski značajnih nuspojava zabilježenih nakon stavljanja lijeka u promet označena je kao nije poznato.
Talk to your doctor, pharmacist or nurse before taking Sildenafil Actavis - If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Sildenafil Actavis - Ako imate anemiju srpastih stanica (poremećaj crvenih krvnih stanica), leukemiju (rak krvnih stanica), multipli mijelom (rak koštane srži).
Stevens-Johnson Syndrome (SJS),*
Stevens-Johnsonov sindrom (SJS), * toksična epidermalna nekroliza (TEN) *
If Sildenafil Actavis is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).
Ako se Sildenafil Actavis uzima s hranom, nastup djelovanja može biti odgođen u usporedbi s uzimanjem natašte (vidjeti dio 5.2).
Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or “chest pain”).
Obavijestite svog liječnika ako uzimate bilo koji od ovih lijekova koji se često koriste za ublažavanje angine pektoris (ili „boli u prsima“).
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period >10 years.
Nuspojave nakon stavljanja lijeka u promet prikupljene su u razdoblju procijenjenom na >10 godina.
Sildenafil Actavis is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Sildenafil Actavis je kontraindiciran u bolesnika koji su izgubili vid na jednom oku zbog nearteritične anteriorne ishemijske optičke neuropatije (NAION), bez obzira je li ta epizoda bila u vezi ili ne s prethodnom izloženošću PDE5 inhibitoru (vidjeti dio 4.4).
- The active substance is sildenafil.
- Djelatna tvar je sildenafil.
The dosing recommendations described in ‘Use in adults' apply to patients with mild to moderate renal impairment (creatinine clearance=30-80 mL/min).
Preporuke za doziranje opisane pod „Primjena u odraslih osoba“ odnose se na bolesnike s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina = 30-80 ml/min).
Healthy, elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years).
Zdravi stariji dobrovoljci (65 godina ili stariji) imali su smanjeni klirens sildenafila što je rezultiralo približno 90% višim koncentracijama sildenafila i aktivnog N-dezmetil metabolita u plazmi u usporedbi s koncentracijama opaženim u zdravih mlađih dobrovoljaca (18-45 godina).
Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP.
Sildenafil je jak i selektivan inhibitor cGMP specifične fosfodiesteraze tipa 5 (PDE5) u korpus kavernozumu gdje je PDE5 odgovorna za razgradnju cGMP.
- If you experience sudden decrease or loss of vision, stop taking Sildenafil Actavis and contact your doctor immediately.
- Ako osjetite iznenadno slabljenje ili gubitak vida, prestanite uzimati Sildenafil Actavis i odmah zatražite savjet liječnika.
The safety and efficacy of combinations of sildenafil with other PDE5 inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction have not been studied.
Sigurnost i djelotvornost kombinacija sildenafila s drugim inhibitorima PDE5, s drugim terapijama za plućnu arterijsku hipertenziju (PAH) koje sadrže sildenafil (REVATIO) ili s drugim oblicima liječenja erektilne disfunkcije nije ispitana.
Sildenafil Actavis contains lactose
Sildenafil Actavis sadrži laktozu
Other medicines and Sildenafil Actavis
Drugi lijekovi i Sildenafil Actavis
Sildenafil Actavis contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Sildenafil Actavis sadrži djelatnu tvar sildenafil koja pripada skupini lijekova pod nazivom inhibitori fosfodiesteraze tipa 5 (PDE5).
What Sildenafil Actavis looks like and contents of the pack
Kako Sildenafil Actavis izgleda i sadržaj pakiranja
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
Cimetidin (800 mg), inhibitor citokroma P450 i nespecifični inhibitor CYP3A4 uzrokovao je 56%-tni porast koncentracija sildenafila u plazmi kada se primjenjivao istodobno sa sildenafilom (50 mg) u zdravih dobrovoljaca.
Paediatric population Sildenafil Actavis is not indicated for individuals below 18 years of age.
Pedijatrijska populacija Sildenafil Actavis nije indiciran za primjenu u osoba mlađih od 18 godina.
You should not take Sildenafil Actavis if you do not have erectile dysfunction.
Ne smijete uzimati Sildenafil Actavis ako nemate poremećaj erekcije.
If you experience any of the following serious side effects stop taking Sildenafil Actavis and seek medical help immediately:
Ako primijetite bilo koju od sljedećih nuspojava, prestanite uzimati Sildenafil Actavis i odmah zatražite medicinsku pomoć:
In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n=9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).
U malom placebom kontroliranom ispitivanju bolesnika s dokumentiranom ranom makularnom degeneracijom povezanom s dobi (n=9) sildenafil (jednokratna doza, 100 mg) nije prikazao značajne promjene u provedenim testovima vida (oštrina vida, Amslerova mreža, raspoznavanje boja simulacijom semafora, Humphreyev perimetar i fotostres).
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Iako specifična ispitivanja interakcija nisu provedena za sve lijekove, populacijska farmakokinetička analiza nije pokazivala djelovanje istodobno primijenjenih terapija na farmakokinetiku sildenafila, grupiranih kao inhibitori CYP2C9 (kao što su tolbutamid, varfarin, fenitoin), inhibitori CYP2D6 (kao što su selektivni inhibitori ponovne pohrane serotonina, triciklični antidepresivi), tiazid i srodni diuretici, diuretici Henleove petlje i oni koji štede kalij, inhibitori angiotenzin konvertirajućeg enzima, blokatori kalcijevih kanala, antagonisti beta-adrenoreceptora ili induktori CYP450 metabolizma (kao što su rifampicin, barbiturati).
There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers (see section 5.1).
Nije bilo učinka na motilitet ili morfologiju spermija nakon jedne peroralne doze od 100 mg sildenafila kod zdravih dobrovoljaca (vidjeti dio 5.1).
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija (>70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing sildenafil in all subsets of the paediatric population for the treatment of erectile dysfunction.
Europska Agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja referentnog lijeka koji sadrži sildenafil u svim podskupinama pedijatrijske populacije u svrhu liječenja erektilne disfunkcije (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
You should not use Sildenafil Actavis with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.
Ne smijete uzimati Sildenafil Actavis zajedno s terapijom za plućnu arterijsku hiperteniziju (PAH) koja sadrži sildenafil ili neke druge inhibitore PDE5.
To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Sildenafil Actavis.
Kako bi se smanjila mogućnost pojave tih simptoma, trebate biti na redovitoj dnevnoj dozi alfa-blokatora prije nego počnete uzimati Sildenafil Actavis.
- Serious skin reactions - this occurs rarely Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.
- Jake kožne reakcije - javljaju se rijetko Simptomi mogu uključivati jako ljuštenje i oticanje kože, plikove u ustima, na genitalijama i oko očiju, vrućicu
What Sildenafil Actavis contains - The active substance is sildenafil.
Što Sildenafil Actavis sadrži - Djelatna tvar je sildenafil.
Rare (³ 1/10000 and
Rijetko (³ 1/10000 do
In volunteers with mild to moderate renal impairment (creatinine clearance=30-80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose.
U dobrovoljaca s blagim do umjerenim poremećajem funkcije bubrega (klirens kreatinina = 30-80 ml/min) nakon uzimanja jednokratne oralne doze od 50 mg nije bilo promjena u farmakokinetici sildenafila.
The mean AUC and Cmax of the N-desmethyl metabolite increased 126% and 73% respectively, compared to age-matched volunteers with no renal impairment.
Srednja AUC i Cmax N-dezmetil metabolita porasla je 126% odnosno 73% u usporedbi s dobrovoljcima odgovarajućim po dobi, bez oštećenja bubrega.
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally-acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.
Analiza podataka sljedećih klasa antihipertenzivnih lijekova: diuretika, beta-blokatora, ACE inhibitora, antagonista angiotenzina II, antihipertenzivnih lijekova (vazodilatatora i onih sa središnjim djelovanjem), blokatora adrenergičkog neurona, blokatora kalcijevih kanala i blokatora alfaadrenoceptora nije pokazala razlike u profilu nuspojava u bolesnika koji uzimaju sildenafil u usporedbi s liječenjem placebom.
Sildenafil Actavis is not indicated for use by women.
Sildenafil Actavis nije namijenjen za primjenu u žena.
- An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
- Alergijska reakcija - javlja se manje često (može se javiti kod do 1 na 100 osoba) Simptomi uključuju iznenadno piskanje, otežano disanje ili omaglicu, oticanje očnih kapaka, lica, usana ili ždrijela.
Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8).
Slučajevi nearteritične anteriorne ishemijske optičke neuropatije, rijetkog stanja, prijavljeni su spontano i u opservacijskom ispitivanju vezano uz uzimanje sildenafila i drugih PDE5 inhibitora (vidjeti dio 4.8).
Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).
Istovremena upotreba riociguata sa PDE5 inhibitorima, uključujući sildenafil je kontraindicirana (vidjeti dio 4.3).
If you have been told by your doctor that you have an intolerance to some sugars, such as lactose, contact your doctor before taking Sildenafil Actavis.
Ako Vam je liječnik rekao da ne podnosite neke šećere, kao što je laktoza, prije nego što počnete uzimati Sildenafil Actavis posavjetujte se sa svojim liječnikom.
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment.
U dobrovoljaca s blagom do umjerenom cirozom jetre (Child-Pugh A i B) klirens sildenafila bio je snižen što je rezultiralo porastom AUC (84%) i Cmax (47%) u usporedbi s dobrovoljcima odgovarajućim po dobi bez poremećaja funkcije jetre.